TY - JOUR
T1 - Results of 1940 embolizations for dural arteriovenous fistulas
T2 - Japanese Registry of Neuroendovascular Therapy (JR-NET3)
AU - Hiramatsu, Masafumi
AU - Sugiu, Kenji
AU - Hishikawa, Tomohito
AU - Nishihiro, Shingo
AU - Kidani, Naoya
AU - Takahashi, Yu
AU - Murai, Satoshi
AU - Date, Isao
AU - Kuwayama, Naoya
AU - Satow, Tetsu
AU - Iihara, Koji
AU - Sakai, Nobuyuki
N1 - Funding Information:
N. Sakai received unrelated consultancy from Achieva Co., Car-diatis Co., Cerenovus/Johnson & Johnson Co., Medtronic Co., MicroVention/Terumo Co., Penumbra Co., Stryker Co., and an unrelated research grant from Terumo Co. K. Iihara received unrelated research grants from Otsuka Pharmaceutical Co., Mit-subishi Tanabe Pharma Co., Kaneka Medix Co., Chugai Pharmaceutical Co., and Eizai Co. M. Hiramatsu, K. Sugiu, T. Hishikawa, S. Nishihiro, N. Kidani, Y. Takahashi, S. Murai, I. Date, N. Kuwayama, and T. Satow had no conflicts of interest to declare.
Funding Information:
This study was supported in part by a Grant-in-Aid (Junkanki-Kaihatsu H24-4-3) from the National Cerebral and Cardiovascular Center, Japan and by Hatazaki Foundation, Kobe, Japan.
Publisher Copyright:
© 2020 AANS.
PY - 2020/7
Y1 - 2020/7
N2 - OBJECTIVE Embolization is the most common treatment for dural arteriovenous fistulas (dAVFs). A retrospective, multicenter observational study was conducted in Japan to clarify the nature, frequency, and risk factors for complications of dAVF embolization. METHODS Patient data were derived from the Japanese Registry of Neuroendovascular Therapy 3 (JR-NET3). A total of 40,169 procedures were registered in JR-NET3, including 2121 procedures (5.28%) in which dAVFs were treated with embolization. After data extraction, the authors analyzed complication details and risk factors in 1940 procedures performed in 1458 patients with cranial dAVFs treated with successful or attempted embolization. RESULTS Transarterial embolization (TAE) alone was performed in 858 cases (44%), and transvenous embolization (TVE) alone was performed in 910 cases (47%). Both TAE and TVE were performed in one session in 172 cases (9%). Complications occurred in 149 cases (7.7%). Thirty-day morbidity and mortality occurred in 55 cases (2.8%) and 16 cases (0.8%), respectively. Non-sinus-type locations, radical embolization as the strategy, procedure done at a hospital that performed dAVF embolization in fewer than 10 cases during the study period, and emergency procedures were independent risk factors for overall complications. CONCLUSIONS Complication rates of dAVF embolization in Japan were acceptable. For better results, the risk factors identified in this study should be considered in treatment decisions.
AB - OBJECTIVE Embolization is the most common treatment for dural arteriovenous fistulas (dAVFs). A retrospective, multicenter observational study was conducted in Japan to clarify the nature, frequency, and risk factors for complications of dAVF embolization. METHODS Patient data were derived from the Japanese Registry of Neuroendovascular Therapy 3 (JR-NET3). A total of 40,169 procedures were registered in JR-NET3, including 2121 procedures (5.28%) in which dAVFs were treated with embolization. After data extraction, the authors analyzed complication details and risk factors in 1940 procedures performed in 1458 patients with cranial dAVFs treated with successful or attempted embolization. RESULTS Transarterial embolization (TAE) alone was performed in 858 cases (44%), and transvenous embolization (TVE) alone was performed in 910 cases (47%). Both TAE and TVE were performed in one session in 172 cases (9%). Complications occurred in 149 cases (7.7%). Thirty-day morbidity and mortality occurred in 55 cases (2.8%) and 16 cases (0.8%), respectively. Non-sinus-type locations, radical embolization as the strategy, procedure done at a hospital that performed dAVF embolization in fewer than 10 cases during the study period, and emergency procedures were independent risk factors for overall complications. CONCLUSIONS Complication rates of dAVF embolization in Japan were acceptable. For better results, the risk factors identified in this study should be considered in treatment decisions.
UR - http://www.scopus.com/inward/record.url?scp=85087893721&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087893721&partnerID=8YFLogxK
U2 - 10.3171/2019.4.JNS183458
DO - 10.3171/2019.4.JNS183458
M3 - Article
C2 - 31252394
AN - SCOPUS:85087893721
SN - 0022-3085
VL - 133
SP - 166
EP - 173
JO - Journal of Neurosurgery
JF - Journal of Neurosurgery
IS - 1
ER -